Penumbra/PEN

$232.32

0.45%
-
1D1W1MYTD1YMAX

About Penumbra

Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.

Ticker

PEN

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Adam Elsesser

Employees

4,200

Headquarters

Alameda, United States

Penumbra Metrics

BasicAdvanced
$9.2B
Market cap
102.89
P/E ratio
$2.32
EPS
0.53
Beta
-
Dividend rate

What the Analysts think about Penumbra

Analyst Ratings

Majority rating from 16 analysts.
Buy

Price Targets

Average projection from 13 analysts.
20.49% upside
High $320.00
Low $240.00
$232.32
Current price
$279.92
Average price target

Penumbra Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.04% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$284.6M
5.06%
Net income
$54.2M
489.13%
Profit margin
19.04%
461.65%

Penumbra Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 47.32%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
$0.23
$0.43
$0.67
-
Expected
$0.11
$0.28
$0.45
$0.40
Surprise
111.17%
54.29%
47.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Penumbra stock

Buy or sell Penumbra stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing